CFO of BeOne Medicines (NASDAQ: ONC) granted performance-based shares

Rhea-AI Filing Summary

BeOne Medicines Ltd. reported that Chief Financial Officer Aaron Rosenberg received equity compensation in the form of ordinary shares linked to performance share units. On March 6, 2026, he was granted 79,014 ordinary shares underlying earned performance share units that are scheduled to vest in 2027, and an additional 40,573 ordinary shares underlying earned performance share units scheduled to vest in 2028.

All of these earned performance share units will vest only if Rosenberg continues to provide service to the company through the respective vesting dates, with unvested awards eligible for accelerated vesting upon certain termination events. Following these awards, his direct ownership increased to 334,919 ordinary shares, reflecting a compensation-related acquisition rather than an open-market purchase.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rosenberg Aaron

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	79,014	$0.00	--
Grant/Award	Ordinary Shares	40,573	$0.00	--

Holdings After Transaction: Ordinary Shares — 294,346 shares (Direct)

Footnotes (1)

1. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosenberg Aaron

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/06/2026		A		79,014(1)	A	$0	294,346	D
Ordinary Shares	03/06/2026		A		40,573(2)	A	$0	334,919	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.

2. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BeOne Medicines (ONC) disclose about its CFO in this Form 4?

BeOne Medicines disclosed that CFO Aaron Rosenberg received two equity awards of ordinary shares tied to performance share units. These grants are part of his compensation and increase his direct share ownership in the company, with vesting scheduled over 2027 and 2028.

How many BeOne Medicines (ONC) shares were granted to the CFO?

The CFO was granted 79,014 ordinary shares underlying earned performance share units vesting in 2027 and 40,573 ordinary shares vesting in 2028. These awards represent compensation, not open-market purchases, and are contingent on continued service to BeOne Medicines.

When do the new BeOne Medicines (ONC) performance share units vest for the CFO?

The earned performance share units underlying 79,014 ordinary shares are scheduled to vest in 2027, and those underlying 40,573 ordinary shares in 2028. Vesting requires the CFO to continue providing service through each vesting date, with potential acceleration on certain termination events.

Are the BeOne Medicines (ONC) CFO’s new share awards immediately owned without conditions?

No, the grants are subject to vesting conditions. The ordinary shares correspond to earned performance share units that vest in 2027 and 2028 only if the CFO continues service. Unvested awards may vest earlier if specific termination events trigger accelerated vesting provisions.

How did these awards change the BeOne Medicines (ONC) CFO’s shareholdings?

After the March 6, 2026 awards, the CFO’s direct holdings rose to 334,919 ordinary shares. This increase reflects compensation-related grants rather than market transactions, providing him with additional equity exposure aligned with BeOne Medicines’ future performance and service-based vesting.

Do the BeOne Medicines (ONC) CFO’s new awards involve a cash purchase of shares?

No, the awards were recorded at a price per share of $0.0000, indicating they were granted as equity compensation rather than bought for cash. They represent performance-based share units that convert into ordinary shares upon satisfying future vesting and service conditions.